Soleno just turned profitable for the first time—right as a major fund made its move.Connecticut-based fund Braidwell initiated a new position in Soleno Therapeutics (SLNO +5.41%) during the third quarter, adding 1.3 million shares worth about $86.7 million, according to a November 14 SEC filing.What HappenedAccording to a Securities and Exchange Commission (SEC) filing dated November 14, Braidwell disclosed a new equity position in Soleno Therapeutics (SLNO +5.41%). The fund acquired nearly 1.3 million sha ...